levoleucovorin and Abortion--Threatened

levoleucovorin has been researched along with Abortion--Threatened* in 1 studies

Other Studies

1 other study(ies) available for levoleucovorin and Abortion--Threatened

Article	Year
A case of twin pregnancy with complete hydatidiform mole and coexisting fetus following IVF-ET. Journal of assisted reproduction and genetics, 2002, Volume: 19, Issue:3 Twin pregnancy consisting of complete hydatidiform mole (H-mole) and a coexisting fetus occurs with an estimated incidence of 1 per 22,000-100,000 pregnancies. The incidence of this unusual twin pregnancy with complete H-mole and a coexisting fetus after in vitro fertilization and embryo transfer (IVF-ET) is not thought to be greater than that of general population. We present an unusual twin pregnancy with complete H-mole and a coexisting fetus that occurred following IVF-ET, which was terminated at 21 weeks of gestation and developed into nonmetastatic gestational trophoblastic tumor. Topics: Abortion, Therapeutic; Abortion, Threatened; Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydatidiform Mole; Infant, Newborn; Leucovorin; Male; Methotrexate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Multiple; Uterine Hemorrhage; Uterine Neoplasms	2002

Article

Year

A case of twin pregnancy with complete hydatidiform mole and coexisting fetus following IVF-ET.

Journal of assisted reproduction and genetics, 2002, Volume: 19, Issue:3

Twin pregnancy consisting of complete hydatidiform mole (H-mole) and a coexisting fetus occurs with an estimated incidence of 1 per 22,000-100,000 pregnancies. The incidence of this unusual twin pregnancy with complete H-mole and a coexisting fetus after in vitro fertilization and embryo transfer (IVF-ET) is not thought to be greater than that of general population. We present an unusual twin pregnancy with complete H-mole and a coexisting fetus that occurred following IVF-ET, which was terminated at 21 weeks of gestation and developed into nonmetastatic gestational trophoblastic tumor.

Topics: Abortion, Therapeutic; Abortion, Threatened; Adult; Antimetabolites, Antineoplastic; Biomarkers, Tumor; Chorionic Gonadotropin, beta Subunit, Human; Combined Modality Therapy; Embryo Transfer; Female; Fertilization in Vitro; Humans; Hydatidiform Mole; Infant, Newborn; Leucovorin; Male; Methotrexate; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy, Multiple; Uterine Hemorrhage; Uterine Neoplasms

2002